Home Sectors Healthcare Present Trend: Gilead Sciences (NASDAQ: GILD)

Present Trend: Gilead Sciences (NASDAQ: GILD)


Gilead Sciences trades as part of the healthcare sector and is part of the biotechnology industry. Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.

Previous Intraday Trading Performance:

The GILD stock showed a previous change of 0.28% with an open at 66.92 and a close of 67.47. It reached an intraday high of 67.61 and a low of 66.34.

SeekingAlpha:  After Humira: AbbVie’s Upa Vs Gilead’s Filgo


The stock has a market cap of $86.5b with 1.3b shares outstanding, of which the float is 1.3b shares. Trading volume reached 5,122,640 shares compared to its average volume of 7,862,454 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Gilead Sciences shares returned -3.68% and in the past 30 trading days it returned 7.20%. Over three months, it changed -4.04%. In one year it has changed -21.61% and within that year its 52-week high was 82.72 and its 52-week low was 60.32. GILD stock is 11.85% above its 52 Week Low.

Our calculations show a 200 day moving average of 70.52 and a 50 day moving average of 67.32. Currently GILD stock is trading -4.33% below its 200 day moving average and may be a good opportunity to buy, but should check other indicators to confirm a buy signal.

SeekingAlpha:  Vertex: Shareholders Might Have Reason To Breathe More Easily


The last annual fiscal EPS for the company was reported at 6.16 that ended on 31st of December 2018, which according to the previous close, that is a PE of 19.22. Based on 8 analyst estimates, the consensus EPS for the next quarter is 1.61. The TTM EPS is 6.16, which comes to a TTM PE of 10.95. Historically, the PE high was 64.20 and the PE low was 5.90. If the stock reached its PE low, that would represent a price of 36.35, which is a decrease of -46.12%.

The following are the last four quarter reported earnings per share:
12-31-2018:  1.34
09-30-2018:  1.70
06-30-2018:  1.75
03-31-2018:  1.37

The dividend per share is currently 2.52, which is a dividend yield of 3.73%. Also, the payout ratio is 40.91%, therefore the dividend is safe according to our calculations.

Base on our calculations, the intrinsic value per share is 51.18, which means it may be overvalued by -31.82%

Indicators to Watch:

Based on the latest filings, there is 125.50% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.21

SeekingAlpha:  In A World Full Of Numbers, These Non-Numeric Factors That Matter More

Fundamental Indicators:

Based on last reported financials, the company’s return on assets is 8.33%, profit margin is 24.52%, price-to-sales is 3.90 and price-to-book is 3.78.

Company Scores:

All scores are out of six:
 2  :Valuation Score
 1  :Past Performance Score
 4  :Financial Strength Score
 2  :Future Growth Score
 4  :Dividend Score
 2  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.